TABLE 2.

Antimalarial activities of different formulations in the P berghei-infected mouse model after a single i.v. dose

Formulation of halofantrineDose (mg/kg)MST (days)bNo. of survivors (n = 10)Mean parasitemia (%) ± SDa on day:
5101432
i.v. solution (8)118 (13-24)035.4 ± 10.543.0 ± 2.631.8 ± 4.1
3>60e1016.0 ± 12.527.5 ± 15.823.0 ± 13.60
10>60e1012.8 ± 8.27.3 ± 0.97.5 ± 6.00
30>60e1013.3 ± 7.32.4 ± 1.42.5 ± 4.60
100f
PLA-POLOX NC1>60c,e830.5 ± 6.742.5 ± 8.022.8 ± 4.90
3>60d,e86.3 ± 2.216.3 ± 0.817.8 ± 3.90
10>60e104.7 ± 2.72.3 ± 1.34.1 ± 1.30
30>60e105.6 ± 3.61.8 ± 2.22.4 ± 1.80
100>60e107.5 ± 1.01.6 ± 1.000
PLA-PEG NC19e (6-12)033.8 ± 7.545.1 ± 1.5
3>60e107.7 ± 2.611.5 ± 3.512.5 ± 6.10
10>60e105.6 ± 3.77.4 ± 1.51.6 ± 1.00
30>60e107.8 ± 3.92.5 ± 2.00.8 ± 0.50
100>60e107.1 ± 2.91.7 ± 1.40.3 ± 0.10
Unloaded PLA NC7 (5-10)032.6 ± 9.2
Untreated control11 (6-24)034.7 ± 6.128.5 ± 7.833.5 ± 12.0
  • a The value on day 3 was 15.3 ± 7.9.

  • b MST, mean survival time. The range is in parentheses.

  • c Two mice died on day 14.

  • d Two mice died on day 12.

  • e Significantly different from controls by Student's t test (95% confidence intervals).